Eiger Announces Interferon Lambda Results This Morning Before the Market Opens

By Steve Kirsch

Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022.

The call is at 5:30 AM Pacific / 8:30 AM Eastern and is open to the public.

I’ll make two predictions:

  1. The drug will have remarkable efficacy against COVID if it was administered early, at the first sign of symptoms. This is based on the trial in Toronto as well as other things I’ve heard. This is likely to be the best drug that the TOGETHER trial has ever tested, even better than fluvoxamine.
  2. The NIH will find a way to complete ignore this drug even though it has a fantastic side effect profile (virtually nil) and is more effective than monoclonals which were approved (greater reduction in viral loads seen)..

We’ll see Thursday morning how accurate my predictions were.